Boehringer Ingelheim Archives | Be Korea-savvy
Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease Due to MASH, with Significant Improvements in Fibrosis

Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease Due to MASH, with Significant Improvements in Fibrosis

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase II trial Survodutide, a novel glucagon/GLP-1 receptor dual agonist, has demonstrated efficacy in people with obesity1, and statistically significant results in MASH2 suggest the potential to [...]

New Collaboration Between Boehringer Ingelheim and Sleip Leverages AI-technology to Help Detect Lameness in Horses

New Collaboration Between Boehringer Ingelheim and Sleip Leverages AI-technology to Help Detect Lameness in Horses

The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses. This partnership delivers on the shared commitment of Boehringer and Sleip [...]

Boehringer Expands Production Site in Greece for New Medicine

Boehringer Expands Production Site in Greece for New Medicine

Ingelheim am Rhein, Germany, Jan. 11 (Korea Bizwire) –  Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, [...]

Drug Agency Retains Approval of Hanmi’s Controversial Lung Cancer Drug

Drug Agency Retains Approval of Hanmi’s Controversial Lung Cancer Drug

SEOUL, Oct. 4 (Korea Bizwire) – South Korea’s health authorities said Tuesday that they have decided to “conditionally” maintain sales approval for a controversial lung cancer treatment developed by the country’s leading drugmaker Hanmi Pharmaceutical Co. amid side effect concerns.  The Ministry of Food and Drug Safety (MFDS) said it will maintain an earlier decision [...]